Circumventing antivector immunity: potential use of nonhuman adenoviral vectors

Lopez-Gordo, E., Podgorski, I. I., Downes, N. and Alemany, R. (2014) Circumventing antivector immunity: potential use of nonhuman adenoviral vectors. Human Gene Therapy, 25(4), pp. 285-300. (doi: 10.1089/hum.2013.228)

Abstract

Adenoviruses are efficient gene delivery vectors based on their ability to transduce a wide variety of cell types and drive high-level transient transgene expression. While there have been advances in modifying human adenoviral (HAdV) vectors to increase their safety profile, there are still pitfalls that need to be further addressed. Preexisting humoral and cellular immunity against common HAdV serotypes limits the efficacy of gene transfer and duration of transgene expression. As an alternative, nonhuman AdV (NHAdV) vectors can circumvent neutralizing antibodies against HAdVs in immunized mice and monkeys and in human sera, suggesting that NHAdV vectors could circumvent preexisting humoral immunity against HAdVs in a clinical setting. Consequently, there has been an increased interest in developing NHAdV vectors for gene delivery in humans. In this review, we outline the recent advances and limitations of HAdV vectors for gene therapy and describe examples of NHAdV vectors focusing on their immunogenicity, tropism, and potential as effective gene therapy vehicles.

• Item Type: Articles
• Additional Information: This is a copy of an article published in Human Gene Therapy © 2014 copyright Mary Ann Liebert, Inc.; Human Gene Therapy is available online at: http://online.liebertpub.com.
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: Lopez Gordo, Miss Estrella
• Authors: Lopez-Gordo, E., Podgorski, I. I., Downes, N., and Alemany, R.
• College/School: College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
• Journal Name: Human Gene Therapy
• Publisher: Mary Ann Liebert
• ISSN: 1043-0342
• ISSN (Online): 1557-7422
• Copyright Holders: Copyright © 2014 Mary Ann Liebert, Inc.
• First Published: First published in Human Gene Therapy 25(4):285-300
• Publisher Policy: Reproduced in accordance with the copyright policy of the publisher